keyword
MENU ▼
Read by QxMD icon Read
search

Immune therapy cancer

keyword
https://www.readbyqxmd.com/read/29656393/cancer-drugs-and-bugs-bacteriotherapy-on-the-rise
#1
EDITORIAL
Alexandra Adamczyk, Astrid M Westendorf
Discussion on how the gut microbiota orchestrates immune responses during cancer therapies and how targeting the microbiota can prevent chemotherapy-induced toxicity.
April 14, 2018: Journal of Leukocyte Biology
https://www.readbyqxmd.com/read/29656345/update-on-the-treatment-of-early-stage-triple-negative-breast-cancer
#2
REVIEW
Priyanka Sharma
Triple-negative breast cancer (TNBC) accounts for 15% of all breast cancers and is associated with poor long-term outcomes compared to other breast cancer subtypes. Currently, chemotherapy remains the main modality of treatment for early-stage TNBC, as there is no approved targeted therapy for this subtype. The biologic heterogeneity of TNBC has hindered the development and evaluation of novel agents, but recent advancements in subclassifying TNBC have paved the way for further investigation of more effective systemic therapies, including cytotoxic and targeted agents...
April 14, 2018: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29655961/chimeric-antigen-receptor-t-cell-therapy-for-non-hodgkin-lymphoma
#3
REVIEW
Armin Ghobadi
Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy. More than 20,000 people in United States, more than 37,000 people in Europe and more than 199,000 people worldwide die of NHL every year. Recent advances in immunotherapeutic approaches for cancer have resulted in development of new classes of very effective immunotherapeutic approaches including chimeric antigen receptor T (CAR-T) cell therapy that are designed to bypass cancer immune evasion. Here, we review recent advances in CAR-T cell therapy for NHL...
April 11, 2018: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/29653339/natural-killer-cells-target-and-differentiate-cancer-stem-like-cells-undifferentiated-tumors-strategies-to-optimize-their-growth-and-expansion-for-effective-cancer-immunotherapy
#4
REVIEW
Kawaljit Kaur, Milica Perišić Nanut, Meng-Wei Ko, Tahmineh Safaie, Janko Kos, Anahid Jewett
Natural killer (NK) cells are known to select and differentiate cancer stem-like cells/undifferentiated tumors via lysis, and secreted/membrane bound IFN-γ and TNF-α respectively, resulting in the control of tumor growth. Several in vivo mouse models including humanized-BLT mice have been used to study the biology and significance of NK cells in selection/differentiation of stem-like tumors within the context of a reconstituted human immune system. In addition, we discuss the evidence and significance of NK cell loss at the pre-neoplastic stage...
April 10, 2018: Current Opinion in Immunology
https://www.readbyqxmd.com/read/29652833/a-lipophilic-ir-780-dye-encapsulated-zwitterionic-polymer-lipid-micellar-nanoparticle-for-enhanced-photothermal-therapy-and-nir-based-fluorescence-imaging-in-a-cervical-tumor-mouse-model
#5
Santhosh Kalash Rajendrakumar, Ning-Chu Chang, Adityanarayan Mohapatra, Saji Uthaman, Byeong-Il Lee, Wei-Bor Tsai, In-Kyu Park
To prolong blood circulation and avoid the triggering of immune responses, nanoparticles in the bloodstream require conjugation with polyethylene glycol (PEG). However, PEGylation hinders the interaction between the nanoparticles and the tumor cells and therefore limits the applications of PEGylated nanoparticles for therapeutic drug delivery. To overcome this limitation, zwitterionic materials can be used to enhance the systemic blood circulation and tumor-specific delivery of hydrophobic agents such as IR-780 iodide dye for photothermal therapy...
April 13, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29652798/the-double-face-of-exosome-carried-micrornas-in-cancer-immunomodulation
#6
REVIEW
Romina Alfonsi, Ludovica Grassi, Michele Signore, Désirée Bonci
In recent years many articles have underlined the key role of nanovesicles, i.e., exosomes, as information carriers among biological systems including cancer. Tumor-derived exosomes (TEXs) are key players in the dynamic crosstalk between cancer cells and the microenvironment while promote immune system control evasion. In fact, tumors are undoubtedly capable of silencing the immune response through multiple mechanisms, including the release of exosomes. TEXs have been shown to boost tumor growth and promote progression and metastatic spreading via suppression or stimulation of the immune response towards cancer cells...
April 13, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29651744/prospects-of-chimeric-antigen-receptor-t-cell-therapy-in-ovarian-cancer
#7
REVIEW
Vishal Jindal, Ena Arora, Sorab Gupta, Amos Lal, Muhammad Masab, Rashmika Potdar
Despite advances in various chemotherapy regimens, current therapeutic options are limited for ovarian cancer patients. Immunotherapy provides a promising and novel treatment option for ovarian cancer. Recently, chimeric antigen receptor (CAR) T cell therapy has shown promising results in hematological tumors and current research is going on in various solid tumors like ovarian cancer. CAR T cells are genetically engineered T cells with major histocompatibility complex-independent, tumor-specific, immune-mediated cytolytic actions against cancer cells...
April 12, 2018: Medical Oncology
https://www.readbyqxmd.com/read/29651624/in-papillary-thyroid-carcinoma-expression-by-immunohistochemistry-of-braf-v600e-pd-l1-and-pd-1-is-closely-related
#8
Yanhua Bai, Ting Guo, Xiaozheng Huang, Qi Wu, Dongfeng Niu, Xinqiang Ji, Qin Feng, Zhongwu Li, Kennichi Kakudo
Immune checkpoint inhibitor therapies targeting PD-L1/PD-1 have been shown to be effective in treating several types of human cancer. In papillary thyroid carcinoma (PTC), little is known about the expression of PD-L1/PD-1 in the tumor microenvironment or its potential correlation with BRAF V600E mutation status. In this study, we examined the expression of PD-L1, PD-1, and BRAF V600E in PTC by immunohistochemistry and investigated the clinical significance of expression status. We studied the expression of PD-L1, PD-1, and BRAF V600E by immunohistochemical staining in 110 cases of PTC with a diameter > 1 cm...
April 12, 2018: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/29651051/collagen-iv-conveyed-signals-can-regulate-chemokine-production-and-promote-liver-metastasis
#9
George Vaniotis, Roni F Rayes, Shu Qi, Simon Milette, Ni Wang, Stephanie Perrino, France Bourdeau, Hanna Nyström, Yi He, Nathalie Lamarche-Vane, Pnina Brodt
Liver metastases remain a major cause of death from gastrointestinal tract cancers as well as from other malignancies such as breast and lung carcinomas and melanoma. Understanding the underlying biology is essential for the design of effective targeted therapies. We previously reported that collagen IV α1/α2 overexpression in non-metastatic lung carcinoma (M27colIV ) cells increased their metastatic ability, specifically to the liver and documented high collagen IV levels in surgical resections of liver metastases from diverse tumor types...
April 13, 2018: Oncogene
https://www.readbyqxmd.com/read/29650897/-radiotherapy-and-new-cancer-drugs-new-side-effects
#10
Satoaki Nakamura
Chemotherapeutic agents(cytotoxic anticancer drugs)have played a central role as cancer drug therapy for a long time. Since the 2000s, molecular targeted drugs have been developed as therapeutic methods that match the standards specifically for cancer cells, and in solid cancers epidermal growth factor receptor(EGFR)and vascular endothelial growth factor(VEGF) have been approved mainly for drugs targeted. The combination therapy of molecular targeted drugs and radiotherapy has been developed to solve the problem of many adverse events of chemo-radiotherapy...
March 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29650841/-a-case-of-advanced-esophageal-cancer-successfully-treated-with-multidisciplinary-therapy
#11
Junji Kawada, Masaya Nishino, Tomoki Hata, Takayuki Ogino, Masateru Okawa, Hiromitsu Hoshino, Miho Okano, Kenichi Nagai, Naruyasu Kakita, Yongkook Kim, Masaki Okuyama, Toshimasa Tsujinaka
We report a case of advanced esophageal cancer that was successfully treated using chemotherapy, operation, and chemoradiotherapy. A 66-year-old man with advanced esophageal cancer(Mt, O-Is, T4[N0.7-stomach], N2, M0, Stage III)was administered chemotherapy(docetaxel[DOC], cisplatin[CDDP], and 5-fluorouracil[5-FU]: DCF). As the esophageal tumor achieved complete clinical response after 2 courses of chemotherapy, lymph node dissection and proximal gastrectomy were performed for the residual tumor. Abdominal CT 3 months after surgery revealed lymph node swelling...
April 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29650809/-molecular-targeted-therapies-for-hereditary-cancer-syndrome
#12
Hideki Shimodaira
Development of molecular targeted drugs has achieved remarkable improvement of systemic cancer therapy. Recently, the several molecular targeted drugs have become available which associated with the status of responsible genes for hereditary cancer syndrome. These drugs would allow to establish specific strategy for hereditary cancer syndrome or sporadic cancers with similar biological phenotype with hereditary cancer. Genetic tests for the diagnosis of hereditary cancer syndrome will have the meaning of biomarker for predicting the efficacy of these molecular targeted drugs...
April 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29650275/metformin-for-non-small-cell-lung-cancer-patients-opportunities-and-pitfalls
#13
REVIEW
Antonin Levy, Jérôme Doyen
Despite exciting advances of the anticancer armamentarium in the recent years, mortality of non-small cell lung cancer (NSCLC) remains high and novel treatments are requisite. Therapy intensification is explored with promising, but expensive and potentially toxic new compounds. Repositioning already existing drugs for cancer treatment could save money and improve patient outcomes in specific contexts. Observational data suggest that use of the standard antidiabetic agent metformin decreases lung cancer incidence and mortality...
May 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29650269/current-perspectives-on-the-crosstalk-between-lung-cancer-stem-cells-and-cancer-associated-fibroblasts
#14
REVIEW
Cristina Alguacil-Núñez, Inés Ferrer-Ortiz, Elena García-Verdú, Pilar López-Pirez, Irene Maria Llorente-Cortijo, Bruno Sainz
Lung cancer, in particular non-small cell lung carcinoma (NSCLC), is the second most common cancer in both men and women and the leading cause of cancer-related deaths worldwide. Its prognosis and diagnosis are determined by several driver mutations and diverse risk factors (e.g. smoking). While immunotherapy has proven effective in some patients, treatment of NSCLC using conventional chemotherapy is largely ineffective. The latter is believed to be due to the existence of a subpopulation of stem-like, highly tumorigenic and chemoresistant cells within the tumor population known as cancer stem cells (CSC)...
May 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29649510/ilt4-functions-as-a-potential-checkpoint-molecule-for-tumor-immunotherapy
#15
REVIEW
Aiqin Gao, Yuping Sun, Guangyong Peng
Immune checkpoint blockade therapy targeting CTLA4 and PD-1/PD-L1 is a promising strategy in the treatment of different types of cancers. However, the clinical success rates of these therapies are still moderate and varied among cancer types. Therefore, identification of alternative and novel checkpoint molecules or interrupting tolerogenic pathways is urgently needed for successful tumor immunotherapy. Immunoglobulin-like transcript 4 (ILT4) is as an immunosuppressive molecule predominantly expressed in myeloid cells, including monocytes, macrophages, dendritic cells and granulocytes...
April 9, 2018: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/29649374/precision-therapy-of-head-and-neck-squamous-cell-carcinoma
#16
P J Polverini, N J D'Silva, Y L Lei
Precision medicine is an approach to disease prevention and treatment that takes into account genetic variability and environmental and lifestyle influences that are unique to each patient. It facilitates stratification of patient populations that vary in their susceptibility to disease and response to therapy. Shared databases and the implementation of new technology systems designed to advance the integration of this information will enable health care providers to more accurately predict and customize prevention and treatment strategies for patients...
April 1, 2018: Journal of Dental Research
https://www.readbyqxmd.com/read/29648839/a-novel-immunoliposome-technology-for-enhancing-the-activity-of-agonistic-antibody-against-tumor-necrosis-factor-receptor-superfamily
#17
Takako Niwa, Yuji Kasuya, Yukie Suzuki, Kimihisa Ichikawa, Hiroko Yoshida, Akiko Kurimoto, Kento Tanaka, Koji Morita
We have developed a technology for efficiently enhancing the anti-cancer apoptosis-inducing activity of agonistic antibodies against the tumor necrosis factor receptor (TNFR) superfamily by the formation of immunoliposomes. To induce apoptosis in cancer cells, agonistic antibodies to the TNFR superfamily normally need cross-linking by internal immune effector cells via the Fc region after binding to receptors on the cell membrane. To develop apoptosis-inducing antibodies that do not require the support of cross-linking by immune cells, we prepared immunoliposomes conjugated with TRA-8, an agonistic antibody against death receptor 5 (DR5), with various densities of antibody on the liposome surface, and evaluated their activities...
April 12, 2018: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/29644387/personalized-cancer-vaccines-adjuvants-are-important-too
#18
REVIEW
Cécile Gouttefangeas, Hans-Georg Rammensee
Therapeutic cancer vaccines have shown limited clinical efficacy so far. Nevertheless, in the meantime, our understanding of immune cell function and the interactions of immune cells with growing tumors has advanced considerably. We are now in a position to invest this knowledge into the design of more powerful vaccines and therapy combinations aimed at increasing immunogenicity and decreasing tumor-induced immunosuppression. This review focuses essentially on peptide-based human vaccines. We will discuss two aspects that are critical for increasing their intrinsic immunogenicity: the selection of the antigen(s) to be targeted, and the as yet unmet need for strong adjuvants...
April 11, 2018: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/29644338/hypothesis-can-the-abscopal-effect-explain-the-impact-of-adjuvant-radiotherapy-on-breast-cancer-mortality
#19
REVIEW
Ismail Jatoi, John R Benson, Ian Kunkler
Radiotherapy is an integral component of loco-regional therapy for breast cancer. Randomized controlled trials indicate that increasing the extent of extirpative surgery primarily reduces the risk of local recurrences, while the addition of radiotherapy to surgery can also reduce the risk of distant recurrences, thereby lowering breast cancer-specific mortality. This may suggest an "abscopal" effect beyond the immediate zone of loco-regional irradiation that favorably perturbs the natural history of distant micrometastases...
2018: NPJ Breast Cancer
https://www.readbyqxmd.com/read/29644214/anti-pd-1-and-anti-ctla-4-therapies-in-cancer-mechanisms-of-action-efficacy-and-limitations
#20
REVIEW
Judith A Seidel, Atsushi Otsuka, Kenji Kabashima
Melanoma, a skin cancer associated with high mortality rates, is highly radio- and chemotherapy resistant but can also be very immunogenic. These circumstances have led to a recent surge in research into therapies aiming to boost anti-tumor immune responses in cancer patients. Among these immunotherapies, neutralizing antibodies targeting the immune checkpoints T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) are being hailed as particularly successful. These antibodies have resulted in dramatic improvements in disease outcome and are now clinically approved in many countries...
2018: Frontiers in Oncology
keyword
keyword
25008
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"